{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:56:57Z","timestamp":1782525417404,"version":"3.54.5"},"reference-count":95,"publisher":"Microbiology Society","issue":"2","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1154347"],"award-info":[{"award-number":["1154347"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1122897"],"award-info":[{"award-number":["1122897"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:p>\n                  <jats:bold>Background.<\/jats:bold> Chikungunya virus (CHIKV) causes chikungunya fever and has been responsible for major global epidemics of arthritic disease over the past two decades. Multiple CHIKV vaccine candidates are currently undergoing or have undergone human clinical trials, with one vaccine candidate receiving FDA approval. This scoping review was performed to evaluate the \u2018efficacy\u2019, \u2018safety\u2019 and \u2018duration of protection\u2019 provided by CHIKV vaccine candidates in human clinical trials.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods.<\/jats:bold> This scoping literature review addresses studies involving CHIKV vaccine clinical trials using available literature on the PubMed, Medline Embase, Cochrane Library and Clinicaltrial.gov databases published up to 25 August 2023. Covidence software was used to structure information and review the studies included in this article.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results.<\/jats:bold> A total of 1138 studies were screened and, after removal of duplicate studies, 12 relevant studies were thoroughly reviewed to gather information. This review summarizs that all seven CHIKV vaccine candidates achieved over 90\u200a% seroprotection against CHIKV after one or two doses. All vaccines were able to provide neutralizing antibody protection for at least 28\u2009days.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions.<\/jats:bold> A variety of vaccine technologies have been used to develop CHIKV vaccine candidates. With one vaccine candidate having recently received FDA approval, it is likely that further CHIKV vaccines will be available commercially in the near future.<\/jats:p>","DOI":"10.1099\/jgv.0.001965","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T15:16:51Z","timestamp":1709219811000},"source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials"],"prefix":"10.1099","volume":"105","author":[{"given":"Shambhavi","family":"Rao","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia"},{"name":"Global Virus Network (GVN) Centre of Excellence in Arboviruses, Griffith University, Gold Coast, QLD, Australia"},{"name":"The Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Erku","sequence":"additional","affiliation":[{"name":"Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia"},{"name":"Global Virus Network (GVN) Centre of Excellence in Arboviruses, Griffith University, Gold Coast, QLD, Australia"},{"name":"The Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-3961","authenticated-orcid":false,"given":"Adam","family":"Taylor","sequence":"additional","affiliation":[{"name":"The Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, 4215, Australia"},{"name":"Global Virus Network (GVN) Centre of Excellence in Arboviruses, Griffith University, Gold Coast, QLD, Australia"},{"name":"School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(55)90080-8"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.58.3.491-562.1994"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-0035"},{"key":"R4","volume-title":"Chikungunya Worldwide Overview","year":"2022"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02449-17"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/MD\/0b013e31806010a5"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.2807\/esm.12.01.00679-en"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-016-0057-4"},{"key":"R9","first-page":"26","article-title":"Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic","volume":"46","author":"Krishnamoorthy","year":"2009","journal-title":"J Vector Borne Dis"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0479-2016"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268808001167"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007575"},{"key":"R13","article-title":"Excess mortality related to chikungunya epidemics in the context of co-circulation of other arboviruses in Brazil","volume":"9","author":"Freitas","year":"2017","journal-title":"PLoS Curr"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.3201\/eid1403.070720"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.3201\/eid1402.071024"},{"key":"R16","article-title":"Number of reported cases of chikungunya fever in the Americas, by country or territory 2013-2014","year":"2015"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7223a5"},{"key":"R18","volume-title":"Autochthonous transmission of chikungunya virus in mainland EU\/EEA, 2007\u2013Present","year":"2007"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08347"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010244"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84417"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz202"},{"key":"R23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed chikungunya vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J Immunol"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.062"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1128\/am.19.2.321-325.1970"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2000.62.681"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01970-16"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.054"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00844-11"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.060"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002124"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00370-12"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.03.016"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1590\/s0104-11692007000300023"},{"key":"R35","volume-title":"Veritas Health Innovation"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.064"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028923"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03453-13"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.3390\/v10030105"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.11.001"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.83527"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03453-13"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01926-14"},{"key":"R44","volume-title":"Valneva Reports Excellent Final Phase 1 Results for Its Chikungunya Vaccine Candidate, Confirms Plans","year":"2018"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160173"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.086"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.21.11546-11554.2003"},{"key":"R48","volume-title":"Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability","year":"2015"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005895"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S181574"},{"key":"R51","volume-title":"Seamless controlled trial to evaluate safety and immunogenicity of chikungunya vaccine in Latin America and Asia","year":"2020"},{"key":"R52","volume-title":"CEPI awards up to US$14.1million to consortium of IVI and Bharat BIOTECH to advance development of chikungunya vaccine in collaboration with Ind-CEPI","year":"2020"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.006"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.3390\/v14050969"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2105"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.083"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.115"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2105"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410x(86)90003-4"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8040231"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24906-y"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.3390\/v11040322"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30238-3"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00641-4"},{"key":"R65","volume-title":"Sets Stage for Phase 3 Study"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2014.1710"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70043-5"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.11.058"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61185-5"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2000.62.681"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116479"},{"key":"R74","volume-title":"Adverse Events Following Immunization (AEFI)"},{"key":"R75","volume-title":"Immunization safety surveillance: Guideline for managers of immunization programmes on reporting and investigating adverse events following immunization","year":"1999"},{"key":"R76","volume-title":"A reader\u2019s guide to safety & adverse event data from vaccine trials","author":"Blogs","year":"2021"},{"key":"R77","article-title":"What is a serious adverse event?"},{"key":"R78","volume-title":"Valneva successfully completes pivotal phase 3 trial of single-shot chikungunya vaccine candidate","author":"France","year":"2022"},{"key":"R79","volume-title":"Guidance for industry: Toxicity grading scale for healthy adult","year":"2007"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1562908"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00226-2"},{"key":"R82","volume-title":"Vaccine efficacy, effectiveness and protection","year":"2021"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz658"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004281"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-183"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22134"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis568"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6521e1"},{"key":"R89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006919"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01780-12"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2023.100018"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151095"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz658"},{"key":"R94","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00226-2"},{"key":"R95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2477"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.001965?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T15:17:02Z","timestamp":1709219822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.001965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1099\/jgv.0.001965","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}